|
Completed
|
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A |
|
Completed
|
NCT04504435 -
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
|
Phase 1 |
|
Completed
|
NCT00004755 -
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
|
Phase 2 |
|
Completed
|
NCT00657618 -
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
|
Phase 1/Phase 2 |
|
Completed
|
NCT04512742 -
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
|
N/A |
|
Recruiting
|
NCT00344188 -
Diagnosis and Treatment of Leishmania Infections
|
|
|
Active, not recruiting
|
NCT03009422 -
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
|
N/A |
|
Recruiting
|
NCT05449717 -
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
|
|
|
Recruiting
|
NCT06307171 -
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
|
N/A |
|
Completed
|
NCT01751048 -
LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
|
Phase 1 |
|
Terminated
|
NCT06124144 -
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
|
Phase 1 |
|
Completed
|
NCT00662012 -
Sodium Stibogluconate Treatment of Leishmaniasis
|
Phase 2 |
|
Completed
|
NCT03993093 -
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
|
|
|
Recruiting
|
NCT03784248 -
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
|
|
|
Withdrawn
|
NCT02429505 -
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
|
|
|
Completed
|
NCT01377974 -
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
|
Phase 2 |
|
Completed
|
NCT01484548 -
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
|
Phase 1 |
|
Completed
|
NCT01300975 -
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
|
Phase 2 |
|
Completed
|
NCT03294161 -
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
|
Phase 2 |
|
Completed
|
NCT00401557 -
Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection
|
|